Table 2.
Patient characteristics of immune-related encephalitis (IRE) cases
| Patient number | Sex | Age | Malignancy | Treatment CPI single agent/combination |
|---|---|---|---|---|
| 1 | M | 70 | SCLC | Anti CTLA4 + chemotherapy |
| 2 | M | 87 | Urothelial carcinoma | Anti PDL1 |
| 3 | F | 49 | Uterine carcinoma | Anti CTLA4 + anti PD1 |
| 4 | F | 71 | Breast cancer | Anti PD1 + chemotherapy |
| 5 | M | 84 | Melanoma | Anti PD1 |
| 6 | M | 59 | Melanoma | Anti PD1 |
| 7 | F | 71 | NSCLC | Anti PD1 |
| 8 | M | 68 | NSCLC, adenocarcinoma | Anti PD1 + chemotherapy |
| 9 | F | 67 | NSCLC, adenocarcinoma | Anti PDl + chemotherapy |
| 10 | F | 67 | Melanoma | Anti PD1 + anti LAG3 |
| 11 | F | 73 | RCC | TKI + anti PD1 |